stockrowGT Biopharma, Inc.
GTBP Healthcare Biotechnology
- EPS
- +98.9%
- Free cash flow
- −41.3%
Quarter to June 2026, against a year earlier
Follow GTBP
Alert me
GT Biopharma, Inc. (GTBP) EV/Sales
As of 6 November 2026, GT Biopharma, Inc. (GTBP) trades at a EV/Sales of 475×. Over the past ten years it has ranged from 67.4× (June 2018) to 26,647,748× (April 2016); the current reading is higher than 42% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2015 | 1,774× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2015 | 1,774× | (34.68%) |
| Jun 2015 | 2,716× | (55.51%) |
| Mar 2015 | 6,105× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PHIO Phio Pharmaceuticals Corp. compare | −25.5× |
| CALC CalciMedica Inc. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| MBRX Moleculin Biotech, Inc. compare | n/m |
| AZR Azora Therapeutics, Inc. compare | n/m |
| BLRX BioLineRx Ltd. compare | 0.9× |
| GTBP GT Biopharma, Inc. | 475× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)